Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD

• Published in: Journal of general internal medicine : JGIM 2022-12, Vol.37 (16), p.4183-4188
• Main Authors: Baalbaki, Nour, Giuliano, Christopher, Hartner, Carrie L., Kale-Pradhan, Pramodini, Johnson, Leonard
• Format: Article
• Language: English
• Subjects: Adolescent; Amides; Anti-Bacterial Agents - therapeutic use; Antibiotics; Antimicrobial agents; Azithromycin; Azithromycin - therapeutic use; beta-Lactams - therapeutic use; Chronic obstructive pulmonary disease; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Disease Progression; Failure rates; Health services; Humans; Internal Medicine; Lung diseases; Mechanical ventilation; Medicine; Medicine & Public Health; Obstructive lung disease; Original Research; Patients; Penicillin; Pulmonary Disease, Chronic Obstructive - diagnosis; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - epidemiology; Retrospective Studies; β-Lactam antibiotics
• ISSN: 0884-8734; 1525-1497
• DOI: 10.1007/s11606-022-07486-5

Background There is a lack of data comparing azithromycin to alternative antibiotic choices in managing COPD exacerbations, making appropriate antibiotic selection controversial. Objective To compare treatment failure in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) receiving azithromycin or beta-lactams. Design Retrospective, multicenter cohort study using logistic regression for multivariable analysis. Patients were included if they were at least 18 years old, admitted with AECOPD, and received at least two consecutive days of either a beta-lactam or azithromycin. Patients were excluded if they received concomitant azithromycin and beta-lactam antibiotics during the first 2 days, had a history of other severe underlying pulmonary diseases, pregnancy, COVID-19, alpha-1 antitrypsin deficiency, or received a corticosteroid for a diagnosis other than COPD. Participants Five hundred ninety-five patients were included, of which 428 (72%) received azithromycin and 167 patients (28%) received a beta-lactam. Main Measures The primary endpoint was treatment failure rate in patients receiving azithromycin versus beta-lactams, which was a composite endpoint defined as in-hospital mortality, admission to intensive care, initiation of invasive mechanical ventilation, initiation of a new antibiotic, steroid therapy escalation, or readmission due to AECOPD within 30 days. Key Results The composite primary outcome occurred in 84 patients (19.6%) in the azithromycin group and 54 (32.3%) in the beta-lactam group ( p